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Abstract Using a human Prostaglandin E2 (PGE2) model
of headache, we examined whether a novel potent and
selective EP4 receptor antagonist, BGC20-1531, may pre-
vent headache and dilatation of the middle cerebral (MCA)
and superﬁcial temporal artery (STA). In a three-way
cross-over trial, eight healthy volunteers were randomly
allocated to receive 200 and 400 mg BGC20-1531 and
placebo, followed by a 25-min infusion of PGE2.W e
recorded headache intensity on a verbal rating scale, MCA
blood ﬂow velocity and STA diameter. There was no dif-
ference in headache response or prevention of the dilation
of the MCA or the STA (P[0.05) with either dose of
BGC20-1531 relative to placebo, although putative thera-
peutic exposures were not reached in all volunteers. In
conclusion, these data suggest that the other EP receptors
may be involved in PGE2 induced headache and dilatation
in normal subjects.
Keywords Prostaglandin E2  EP4 receptor antagonist 
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Introduction
The arachidonic acid metabolite prostaglandin E2 (PGE2)
plays an important physiological role in the human body
including the regulation of vascular tone [1] and modula-
tion of pain [2]. PGE2 acts via four different G-protein-
coupled receptor subtypes: EP1,E P 2,E P 3 and EP4 [3].
Once activated by PGE2,E P 1 and EP3 receptors mediate
Ca
2? mobilisation and decrease levels of cAMP, which
leads to smooth muscle contraction [4]. In contrast, PGE2
action on EP2 and EP4 stimulates adenylate cyclase and
thereby causes relaxation of vascular smooth muscles [5].
It has been demonstrated that PGE2-mediated vasodilata-
tion of the human middle cerebral (MCA) and meningeal
arteries (MMA) occurs primarily due to activation of the
EP4 receptors and the EP4 receptor antagonist, AH 23848,
is able to attenuate the PGE2 vasodilating response [6].
PGE2, as a principal pro-inﬂammatory prostanoid, plays a
role in nociceptive processing [7]. It has both direct acti-
vating and sensitizing effects on sensory neurones [8].
Furthermore, increased levels of PGE2 caused up-regula-
tion of the EP4 receptor subtype in rat sensory dorsal root
ganglion (DRG) neurons, but not EP1 and EP3 receptor
subtypes [9]. Given that sensitization of the sensory neu-
rons mediated mainly through the EP4 receptors [10] it has
been suggested that the prostanoid EP4 receptor may be a
potential target for the treatment of pain [11].
A novel selective and potent EP4 receptor antagonist,
BGC20-1531, has been tested in an in vitro human study
[12]. BGC20-1531 antagonized PGE2-mediated dilatation
of human middle cerebral and middle meningeal artery
rings, pre-contracted with phenylephrine. It has therefore
been suggested that BGC20-1531 has the potential to
alleviate the symptoms of migraine pain caused by dila-
tation of cerebral arteries [12]. A human PGE2 model of
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PGE2 induces dilatation of cranial arteries and causes
headache in healthy subjects [13]. Whether BGC20-1531
can block the PGE2 induced responses in humans has
previously not been studied.
The aim of the present study was to evaluate the effect
of two different single oral doses of the EP4 receptor
antagonist BGC20-1531 on PGE2-induced dilatation of
cranial vessels and headache in a randomised, double blind,
placebo-controlled, three-way intra-individual crossover
study.
Methods
Design and subjects
The study was designed as a randomised, double blind,
placebo-controlled, three-way intra-individual crossover
study. Eight healthy volunteers (5 male and 3 female), mean
age 24 years (range 21–30 years) and mean weight 75.7 kg
(range 67–93.5 kg) completed the study. Subjects had no
history or family history of migraine, or any other type of
headache (except episodic tension-type headache less that
once a month) and no previous serious somatic, psychiatric
orinfectious diseases.Physicaland neurologicexamination,
electrocardiography (ECG), clinical-chemical and haema-
tological screenings were done on the day of enrolment.
All subjects were randomly assigned to receive BGC20-
1531 200 mg, BGC20-1531 400 mg or placebo, followed
75 min later by an infusion of PGE2 at 0.40 lg/kg/min
over 25 min on three different days at intervals of at least
1 week. The study drug BGC20-1531 and equivalent pla-
cebo were provided by BTG International Ltd, London,
UK, and randomised and blinded by the central pharmacy,
Herlev Hospital, Denmark. The randomization code was
kept in the hospital during the study and the unblinding
procedure was ﬁrst performed after the study was
completed. PGE2 was purchased from Cayman Pharma,
Neratovice, Czech Republic. The dose of PGE2 (0.40
lg/kg/min) was selected based on a PGE2-induced head-
ache study in healthy volunteers [13].
The study protocol was approved by the Ethics Com-
mittee of the Country of Copenhagen (VEK H-D-2008-
134), Danish Medical Agency (EudraCT 2008-008713-20)
and Danish Data Protection Agency and performed in
accordance with the Helsinki Declaration of 1964, as
revised in Edinburgh in 2000. The study was registered on
http://www.clinicaltrials.gov. All subjects gave written
informed consent to participate in the study. The trial was
conducted according to the protocol and Good Clinical
Practice (GCP), and monitored externally by the GCP unit
from the Copenhagen University Hospital.
Headache intensity and adverse events
To record headache intensity, a 10-point verbal rating scale
(VRS) was used, where 0 indicated no headache; 1 indi-
cated a different sensation, pounding or throbbing, but not
necessarily painful; 5 indicated moderate headache and 10
indicated worst imaginable headache [14]. Subjects were
encouraged to self-report any changes in their well-being
during the study. Subjects were questioned about the
presence of adverse events (AEs), headache and accom-
panying symptoms according to the International Headache
Classiﬁcation (IHC) [15]a tT-75, T-30, T0 and then every
10th min until T90. During the out-of-hospital period,
deﬁned as a period after discharge and until bedtime, all
subjects were carefully instructed to make hourly record-
ings of headache and accompanying symptoms according
IHC [15] and any other AEs. All AEs were classiﬁed as
related or not related to the study drug by the investigator.
Subjects were allowed to take rescue medication of their
own choice after consulting the study physician.
Transcranial Doppler and C-scan
Blood ﬂow velocity was recorded in the middle cerebral
artery (VMCA) by a Transcranial Doppler (TCD) ultraso-
nography (2 MHz) with handheld probes (Multidop X;
DWL, Sipplingen, Germany) [13]. The recordings were
performed bilaterally and simultaneously with measure-
ments of end-tidal partial pressure of pCO2 (PetCO2),
obtained with an open mask without any respiratory
resistance (ProPac Encore
; Welch Allyn Protocol, Bea-
verton, OR, USA) as previously described [16]. A ﬁxed
point was used with the best possible signal along the
MCA, as close as possible to the bifurcation of the anterior
cerebral artery and MCA. The ﬁx point was marked and
noted and was reused in each participant for all recordings.
All measurements were done by the same skilled labora-
tory technician.
A high resolution ultrasound scanner, C-scan (20 MHz,
bandwidth 15 MHz; Dermascan C; Cortex Technology,
Hadsund, Denmark) was used to measure the diameter of
the frontal branch of the left superﬁcial temporal artery
(STA) and the left radial artery (RA). All C-scans were
performed in the same place as ensured by markings drawn
on the skin. The coordinates of the marks were kept for
reuse in the following trial days. All measurements within
the same study subject were done by the skilled laboratory
technician.
Pharmacokinetics
Blood samples for the plasma concentration of BGC20-
1531 were collected at T-75, T0, T30, T60 and T90 on each
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123study day in Vacuette
 Lithium Heparin 4 ml tubes
(Greiner Bio-one, Austria). Samples were immediately
stored on ice and then separated by centrifugation at
1,5009g and 4C for 10 min. Two identical aliquots
of plasma were transferred in to polypropylene tubes
(Sarstedt, Germany) and stored at -25C until analyzed at
Simbec Research Ltd, UK.
BGC20-1531 analytical methods
Plasma concentration of BGC20-1531 was determined by
liquid chromatography with tandem mass spectrometry
detection (LC-MS-MS). The analyses was performed using
atmosphericpressureionizationwithturboionsprayfollowed
by multiple reaction monitoring (MRM) of the characteristic
ion transitions for BGC20-1531 and internal standard.
Trial procedure
Subjects were required to limit alcohol intake to 2 units per
day for 7 days before the ﬁrst dose and until the trial period
was ﬁnished and to avoid alcoholic beverages entirely for
2 days prior to and 2 days after each treatment session.
Subjects had to abstain from caffeine intake 2 days before
the ﬁrst dosing and until the end of the study and cocoa and
chocolate were not allowed 24 h before the dosing day. All
subjects were non-smokers. Use of pharmacologic agents
apart from oral contraceptives were not permitted. Subjects
fasted overnight and reported to the laboratory at 8 a.m. and
were conﬁrmed to be headache-free. Subjects rested in the
supine position throughout the study period from time
-75 min (start of study period, 75 min prior to the infusion)
to T90 (end of study period, 90 min post infusion). The pro-
cedures were performed in a quiet room at room temperature
between 21 and 24.7C. Two intravenous catheters Venﬂon

(Becton Dickton, Sweden) were inserted into the antecubital
veins for the PGE2 infusion and blood sample collection for
BGC20-1531 plasma concentration analysis. The subjects
rested for at least 30 min before T-75 values of ﬂow velocity
in the middle cerebral artery (VMCA), diameters of STA and
RA, mean arterial blood pressure (MAP), heart rate (HR),
PetCO2, transcutaneous arterial oxygen saturation (SAT),
ECG, headache score and AEs were recorded.
Following the baseline measurements, subjects were
randomized to BGC20-1531 200 mg, BGC20-1531
400 mg or placebo. At T0, the infusion of PGE2 (0.40 lg/
kg/min) was initiated by a time and volume controlled
infusion pump (Braun Perfuser, Melsungen, Germany).
The timing of the infusion ensured that a steady state of
BGC20-1531 was reached, as the Tmax was predicted to be
approximately 60 min.
All measurements were recorded at T-75, T-30, T0 and
then every 10th min until T90. MAP and HR were measured
by an auto-inﬂatable cuff (ProPac Encore
; Welch Allyn
Protocol, Beaverton, OR, USA). ECG was obtained con-
tinually using Cardiofax V (Nihon-Cohden, Japan) and
recorded on paper at time as described above.
Statistics
Vascular variables are presented as mean ± SD and as
mean percentage from baseline. Headache scores are pre-
sented as median and quartiles. As we did not record any
vascular or headache responses after BGC20-1531 admin-
istration during T-75 to T0 baseline was deﬁned as T0 before
start of PGE2 infusion. Immediate headache was deﬁned as
any headache during the in-hospital period (0–90 min) and
delayed headache (1.5–11 h) was deﬁned as any headache
during the out-of-hospital period. The data were baseline-
corrected and the area under the curve for the time period
T0–T90 (AUC) for VMCA, headache score, MAP, HR and
PetCO2 was calculated, using the trapezium rule [17].
The sample size was calculated based on proven dif-
ference between treatments, measured as reduced pain
intensity on the VRS at 5% signiﬁcance (one-sided) with
90% power. We assumed 20% deviation on the VRS for
each study subject and 70% reduction of pain intensity was
considered to be clinically signiﬁcant, therefore 8 subjects
were included [18].
The primary end-points were differences in the AUC for
headache score (AUCheadache score) between active and
placebo arm, placebo versus BGC20-1531 200 mg and
placebo versus BGC20-1531 400 mg. The secondary
end-points were differences in the AUC for VMCA
(AUCVMCA), STA (AUCSTA), RA (AUCRA), PetCO2
(AUCPetCO2), MAP (AUCMAP) and HR (AUCHR) between
placebo and two active treatment arms. To test the statis-
tical difference between the variables we applied a paired,
two-way t test for vascular data, the Wilcoxon signed ranks
test for headache score, and the McNemar test for AEs. To
explore possible changes over time for vascular variables
we conducted post hoc analysis by repeated measures one-
way ANOVA (including the Dunnett post hoc test).
Five percent (P\0.05) was accepted as the level of
signiﬁcance. All analyses were performed with PASW
Statistics 18 for Windows (SPSS Inc., Chicago, IL, USA).
Post hoc exploratory analyses were performed using
GraphPad Prism
 (GraphPad Software Inc., CA, USA).
Results
Eight healthy volunteers completed the study. 11 subjects
were enrolled with 3 participants being withdrawn after the
ﬁrst day of dosing. One was withdrawn due to severe chills
and shivering during PGE2 infusion, another due to an
J Headache Pain (2011) 12:551–559 553
123unspeciﬁc T-wave inversion in the pre-cordial leads on
ECG and the third due to a drop in diastolic blood pressure
below 40 mmHg, which was a safety limit according to the
study protocol.
Baseline values
There were no differences in baseline recordings for any
variables between placebo and active days. There were no
differences in baseline velocity in the middle cerebral
artery (VMCA) between the left and the right side on all
three study days (data not shown).
Effect of BGC20-1531 on PGE2-induced headache
The incidence of immediate and delayed headache is
shown in Table 1. There was a large variation in the
severity of headache between the subjects on placebo day
and we found no difference in area under the curve (AUC)
for headache between both pretreatment days and placebo
day (BGC20-1531 200 mg: P = 0.14; BGC20-1531
400 mg: P = 0.173) (Fig. 1).
Effect of BGC20-1531 on velocity of middle cerebral
artery
We found no difference in the AUCVMCA between placebo
and BGC20-1531 200 mg (P = 0.849) and 400 mg
(P = 0.529) (Fig. 2). There was no difference in the AUC
for end-tidal partial pressure of pCO2 (PetCO2) between
both pretreatment days and placebo day (BGC20-1531
200 mg: P = 0.700; BGC20-1531 400 mg: P = 0.712).
Explorative ANOVA analysis revealed signiﬁcant changes
over time in VMCA after placebo (P\0.05) but not after
BGC20-1531 200 and 400 mg (P[0.05). As expected,
post hoc Dunnetts test showed a signiﬁcant drop in VMCA
at T20 after PGE2 infusion on placebo day compared to
baseline (P\0.05).
Effect of BGC20-1531 on diameter of superﬁcial
temporal and radial arteries
The superﬁcial temporal artery AUC (AUCSTA)o n
BGC20-1531 200 mg day was signiﬁcantly larger than on
placebo day (P = 0.033). We found no difference in the
AUCSTA between placebo and BGC20-1531 400 mg day
(P = 0.451) (Fig. 3). There was no difference in the radial
artery AUC (AUCRA) between each pretreatment day
compared with placebo day (P = 0.678 and P = 0.575 on
BGC20-1531 200 mg and BGC20-1531 400 mg pretreat-
ment day respectively).
Peripheral hemodynamics
We found no difference in the AUC for mean arterial blood
pressure (AUCMAP) between placebo and BGC20-1531
200 mg day (P = 0.267) and placebo and BGC20-1531
400 mg day (P = 0.450). There was also no difference in
the AUCHR on placebo day compared with the AUCHR on
BGC20-1531 200 mg (P = 0.799) day and 400 mg day
(P = 0.074).
Pharmacokinetic proﬁle of BGC20-1531
The highest plasma concentration of BGC20-1531 in our
study was detected 75 min after oral administration of
BGC20-1531 200 and 400 mg at T0 (Fig. 4). No plasma
BGC20-1531 was detected in samples taken on placebo
day. The AUC plasma concentration on pretreatment with
BGC20-1531 400 mg was signiﬁcantly larger compared to
the AUC plasma concentration on BGC20-1531 200 mg
(P = 0.036) (Fig. 4). Putative therapeutic concentrations of
C10,000 ng.hr/ml were only reached in 5 out of 8 subjects.
Effect of BGC20-1531 on PGE2 related AEs
We found no difference in incidence of the AEs between
the trial days (Table 2). No adverse events were reported
during the pre-infusion period T-75–T0 except one partic-
ipant who had an asymptomatic T-way inversion on ECG
during pre-infusion period. The ﬁnding was deﬁned by
cardiologist as non-speciﬁc, but a decision was taken to
exclude the participant from further experiments.
Discussion
To our knowledge, this is the ﬁrst study where a potent and
selective EP4 receptor antagonist, BGC20-1531, has been
tested in a human model of headache. The main result was
that the speciﬁc EP4 receptor antagonist did not prevent
PGE2 induced headache in normal volunteers in this study.
Table 1 Incidence of Prostaglandin E2 (PGE2)-induced immediate
and delayed headache in eight healthy subjects
Placebo
plus
PGE2
BGC20-1531
200 mg
plus PGE2
BGC20-1531
400 mg
plus PGE2
Incidence of immediate
headache
66 7
Incidence of delayed
headache
11 1
McNemar test showed no difference in incidence of immediate and
delayed headache between placebo and BGC20-1531 200 and 400 mg
(P[0.05)
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bral haemodynamics [19]. In vitro studies have shown that
PGE2 induces dilatation of human MCA and MMA [6, 12].
Similar results have also been obtained in cerebral and
cranial arteries of animals [12, 20, 21]. However, in vivo
animal studies have yielded conﬂicting results. An open
cranial window model demonstrated that topical applica-
tion of PGE2 caused dilatation of small and large pial
arterioles in cat [22]. In a closed cranial window model, it
caused dilation of the pial arteries in newborn pigs [23].
PGE2-induced dilatation of canine common carotid artery
was also reported [12]. In the closed cranial window
model, intracarotid administration of PGE2 caused dilata-
tion of dural arteries but not pial arteries [20]. The
conﬂicting data on whether or not PGE2 causes dilatation
of arteries in different animal’s models may critically
depend on the availability of PGE2 directly at the smooth
muscle receptors, which is certainly different between
luminal and abluminal administration.
PGE2-induced headache and EP4 receptor antagonist
We have previously demonstrated in a double blind ran-
domized crossover experiment, that intravenous PGE2
induces headache in healthy subjects [13]. Mean headache
data recorded on the placebo day in the present study were
in agreement with our previous study [13]. Given that the
EP4 receptor antagonist, BGC20-1531 is highly selective
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123[12], doses used in the present study should almost com-
pletely block EP4 receptors [12]. We therefore expected
amelioration of PGE2-induced headache. However, two
single doses of BGC20-1531 did not prevent the PGE2-
induced headache. Oral dosing with BGC20-1531 (200 and
400 mg) in healthy volunteers has resulted in consistent
plasma exposure in previous clinical studies with relatively
low inter-subject variability (unpublished observations;
single ascending dose study Cmax 9,850 ± 2,900 and
22,700 ± 5,500 ng/ml at the 200 and 400 mg dose,
respectively). The pharmacokinetic proﬁle in the current
study showed that exposure to BGC20-1531 was more
variable (Cmax 11,850 ± 5,800 and 21,100 ± 11,600 ng/
ml at the 200 and 400 mg dose, respectively) and reached
putative therapeutic concentrations in 5 out of 8 subjects
(\10,000 ng hr/ml). However, results from the ﬁve sub-
jects with sufﬁcient plasma exposure did not indicate an
effect of BGC20-1531.
It has previously been shown that other EP receptor
subtypes such as EP1 [24, 25], EP2 [24, 25], EP3 [25],
EP3A/a [24], EP3B[ 24], EP3b [24], EP3C[ 10] are
expressed in sensory neurons and are involved in PGE2-
induced sensitization [10, 24, 26, 27] and hyperalgesia
[28]. Moreover, EP1 receptor antagonist GSK345931A
attenuated hypersensitivity in a dose related manner in a
preclinical model of inﬂammatory pain [29] and EP3
receptor knockout mice had reduced licking responses in
the second phase of the formalin assay [30]. Aside from the
possible activation of the other EP receptor subtypes in the
presence of blocked EP4 receptors, PGE2 may also stimu-
late release of other vasoactive substances. It has been
shown that EP2 receptor selective agonist, butaprost, as
well as EP3[EP2 receptor agonist, misoprostol, stimulate
release of the vasodilator neuropeptide, calcitonin-gene
related peptide (CGRP), which is well-known to be
involved in the pathogenesis of neurovascular headaches
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123[31]. Thus, we believe that involvement of the other PGE2
receptors subtypes is the most likely explanation of our
headache results. Although due to the PK variability and
low exposures noted with BGC20-1531, this does not
preclude an involvement of the EP4 receptor subtype.
EP4 receptor expression and EP4 receptor mediated
dilatation of the intra- and extracerebral vessels
In our previous study on PGE2 induced headache in healthy
subjects, we showed dilatation of MCA (13.9%, mean
change from baseline) and STA (23.5%). The current
vascular data, recorded on the placebo day were in agree-
ment with this study [13]. It is well reported that PGE2-
induced dilatation of cerebral blood vessels is mediated via
EP2 and EP4 receptors [5, 32]. To our knowledge, very few
immunohistochemical studies have reported the distribu-
tion of EP4 receptors in human vasculature. EP4 receptors,
but not EP2 receptors are highly expressed in human
pulmonary vein [33] and human renal artery [34] whereas
EP4 and EP2 receptors show low expression in human
pulmonary artery [33]. No data are available at present to
show the distribution of EP4 and EP2 receptors in human
intra- or extracranial arteries or in radial artery. Previous in
vitro studies have reported that PGE2-induced dilatation of
both human and animal isolated MCA [6, 12, 20] and
MMA [12, 20] can be abolished by BGC20-1531 [6, 12,
20]. Furthermore, a speciﬁc EP2 receptor agonist causes no
dilatation during stimulation [6, 20]. This suggests that
PGE2-induced dilatation of those vessels is mediated
through EP4 receptors.
In the present study, EP4 receptor antagonist BGC20-
1531 did not prevent PGE2-induced velocity drop of MCA
velocity and thereby dilatation of MCA. Interestingly,
exploratory ANOVA analysis revealed statistical changes
over time in VMCA on the placebo day, but not on the active
treatment day. Although there was no statistical effect of
BGC20-1531on PGE2 responses, we found a modest trend
of less velocity drop (Fig. 2). A weak antagonist effect
could be due to low permeability of BGC20-1531 through
the blood brain barrier and/or by the activation of EP2
receptors by PGE2. The prolonged and increased dilatation
of STA after 200 mg BGC20-1531 is difﬁcult to explain. It
is possible that EP2 receptors are responsible for the
dilating effect of PGE2 in the STA. The EP2 receptor has a
shorter cytoplasmatic carboxyl terminus [35–37] and
therefore, undergoes less internalization [38] and desensi-
tization [39] after exposure to PGE2 compared to the EP4
receptor. In contrast to EP4,E P 2 remains sensitive to
metabolites of PGE2 [39, 40]. Hence, the activation of EP2
receptors could both prolong and intensify dilatation of
STA. Future studies on EP2/EP4 receptors distribution in
human STA, MCA and MMA may clarify these issues.
In conclusion, the selective blockade of EP4 receptors
did not prevent PGE2 induced headache or vasodilatation.
It should be noted that the present study was sufﬁciently
powered to demonstrate effect based on previous study
[41], however the low exposures of BGC20-1531 in 3 out
of 8 volunteers may have contributed to the negative out-
come in this study. Furthermore, we cannot exclude the
PGE2-induced activation of the other EP receptors as well
as possible low BBB permeability of the EP4 receptor
antagonist. Therefore, further investigations of both PGE2
and EP4 receptors role in the pathogenesis of the neuro-
vascular headache are hence worthy.
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plus
PGE2
BGC20-1531
200 mg plus
PGE2
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400 mg plus
PGE2
Headache 6 6 7
Nausea 2 0 2
Photophobia 1 2 3
Phonophobia 0 0 0
Flushing 8 8 7
Heat sensation 6 5 5
Palpitation 4 7 4
Low back pain 1 0 1
Tightness in chest 4 3 2
Stiff muscles 2 1 2
Chills 1 1 0
Increased mucus
production in throat
32 2
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11 2
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injection place
13 1
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which mimics
menstruation
11 1
Urge to void 3 1 2
Thirst 3 2 2
Face heat sensation 0 0 1
There was no difference between occurrence of AEs on placebo and
BGC20-1531 200 mg pretreatment and BGC20-1531 400 mg pre-
treatment (P[0.05, McNemar test)
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